.jpeg)
2026-04-22 07:26:16
As a bispecific T cell engager, Tarlatamab revolutionizes cancer treatment by activating immune attacks. This guide outlines unique immune-related adverse events (irAEs) and global management strategies.
2026-04-22 07:18:24
As a 3rd-generation EGFR-targeted therapy, Almonertinib offers significant benefits for NSCLC, but safety management—focused on lung toxicity, skin reactions, cardiac risks, and drug interactions—is crucial for long-term use.
2026-04-21 04:14:58
This article specifies home storage requirements for the oral HSP90 inhibitor Pimitespib, covering temperature, humidity and light protection to maintain drug stability and efficacy, supporting long-term medication management.
2026-04-21 03:28:51
Sirolimus (brand name Rapamune) is a macrolide mTOR immunosuppressant developed by Wyeth. It is mainly used for the prophylaxis of rejection after renal transplantation and the treatment of lymphangioleiomyomatosis. This article systematically introduces its indications, dosage, adverse reactions and safe administration specifications.
2026-04-21 02:57:14
Lusutrombopag is an oral small-molecule thrombopoietin receptor agonist approved by the U.S. FDA in 2018 for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure. This article details its core mechanism of action, standard dosage regimen, and proper drug storage requirements.
2026-04-21 02:42:40
Icotyde (generic name: Icotrokinra) is a medication that works by modulating the immune system. It has a relatively mild overall side effect profile, but still requires close monitoring of drug reactions by patients and healthcare providers. This article details its common side effects and targeted mitigation strategies, core pharmacokinetic characteristics, and standard drug storage requirements.
2026-04-21 02:29:17
Cemiplimab (brand name Libtayo) is a fully human PD-1 immune checkpoint inhibitor developed by Regeneron Pharmaceuticals. Approved by the U.S. FDA in September 2018, it was the first breakthrough therapy for metastatic or locally advanced cutaneous squamous cell carcinoma. By blocking PD-1 ligand binding to activate T-cell anti-tumor activity, it is now approved for the treatment of multiple cancers including cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer.
2026-04-20 04:21:47
Enfortumab vedotin (brand name Padcev) is the world's first Nectin-4-targeted antibody-drug conjugate (ADC) co-developed by Seagen and Astellas. It has been approved by the FDA, EMA, and other global regulatory agencies for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma.
2026-04-20 04:06:29
Urece (generic name: dotinurad) is a highly selective urate reabsorption inhibitor developed by Fuji Yakuhin, Japan. It has been approved in Japan, China, and other countries for the treatment of adult patients with gout and hyperuricemia.
2026-04-20 03:57:16
Mirvetuximab soravtansine (brand name Elahere) is the world's first folate receptor alpha (FRα)-targeted antibody-drug conjugate (ADC) developed by ImmunoGen, USA. It has received full approval from the FDA, EMA, and other global regulatory agencies for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
2026-04-15 05:07:26
Mitotane, the sole approved drug for adrenocortical carcinoma (ACC), is reaffirmed as the preferred adjuvant therapy in the latest NCCN Guidelines 2026. This article dissects its mechanisms, dosing protocols, safety considerations, and international pricing trends, offering authoritative guidance for Hong Kong, Macau, and overseas patients.
2026-04-13 07:05:12
Anagrelide is a platelet-lowering agent used in essential thrombocythemia (ET). Learn about its indications, mechanism, potential side effects, and expert guidance for safe use in managing elevated platelet counts.
